Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Transcript
As ISPOR prepares for the annual meeting in Boston in May, how is it handling the uncertainty of an Affordable Care Act repeal? What other topics will the meeting focus on?
Our first plenary in Boston is going to feature a panel of 4 leading health economists. Two that have worked with the Democrats—Jonathan Gruber and David Cutler—and 2 that have tended to work with Republicans—Joe Antos and Gail Wilensky. Given what just happened [with the American Health Care Act] we expect it to be a very lively discussion.
Our second plenary is on the leading edge of how we look at healthcare behaviors. It's called "Social Networking Interventions and Population Health." And it's being given by Nicholas Christakis of Yale. I'm really anxious to hear that one. And our third one will be very aligned with what we talked about [at AMCP 2017]. The title is "When Do You Really Need Randomized Clinical Trials?" And we'll have Sebastian Schneeweiss and Rob Califf, who was just FDA commissioner, and Steven Goodman to talk about those topics.
Plus, about another 100 sessions on a variety of current scientific and policy topics. So we're really excited about it.
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference for Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, has been made in the fight against the HIV pandemic given the current political climate.
Read More
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More